A Chinese scientist who set off an ethical debate with claims that he had made the worlds first genetically edited babies three, according to a Chinese court was sentenced to three years in prison because of his research, state media, the Associated Press and the New York Times have reported.
He Jiankui, who was convicted of practicing medicine without a license, was also fined 3 million yuan ($430,000) by a court in the southern city of Shenzhen, Chinas official Xinhua News Agency reported on Monday. Two other researchers involved in the project received lesser sentences and fines.
The verdict said the three defendants had not obtained qualification as doctors, pursued fame and profits, deliberately violated Chinese regulations on scientific research, and crossed an ethical line in both scientific research and medicine, according to Xinhua. It also said they had fabricated ethical review documents.
The court also confirmed a third birth, saying the researchers were involved in the births of three gene-edited babies to two women. It said all three scientists pleaded guilty during the trial, which Xinhua reported was closed to the public because of privacy concerns.
Hes declaration made him a pariah among scientists, cast a harsh light on Chinas scientific ambitions and embroiled other U.S. scientists who were connected to He. Although He offered no proof and did not share any evidence or data that definitively proved he had done it, his colleagues had said it was possible that he had succeeded, The New York Times reported.
U.S. scientists who knew of Hes plans came under scrutiny. Hes former academic adviser, Stephen Quake, a star Stanford University bioengineer and inventor, was cleared of any wrongdoing after an investigation into his interaction with his former student. Rice University has been investigating Michael Deem, Hes doctoral adviser, because of allegations that he was actively involved in the project.
Duke engineers improve CRISPR genome editing with biomedical tails
He, the lead researcher, shocked the scientific world when he announced in November 2018 that he had altered the embryos of twin girls who had been born the same month. He described his work in exclusive interviews with The Associated Press.
The announcement sparked a global debate over the ethics of gene editing. He said he had used a tool called CRISPR to try to disable a gene that allows the AIDS virus to enter a cell, in a bid to give the girls the ability to resist the infection. The identity of the children has not been released, and it isnt clear if the experiment succeeded.
The CRISPR tool has been tested elsewhere in adults to treat diseases, but many in the scientific community denounced Hes work as medically unnecessary and unethical, because any genetic changes could be passed down to future generations. The U.S. forbids editing embryos except for lab research.
He, who is known as JK, told the AP in 2018 that he felt a strong responsibility to make an example, and that society would decide whether to allow the practice to go forward. He disappeared from public view shortly after he announced his research at a conference in Hong Kong 13 months ago, apparently detained by authorities, initially in an apartment in Shenzhen, a city in Guangdong province that borders Hong Kong.
It wasnt clear if the three-year prison term includes any of the time he has already spent in Chinese custody.
A Chinese scientist said the sentence should have been harsher to deter others. Kehkooi Kee, a Tsinghua University researcher who conducts gene-editing research on stem cells, also said that He should be held responsible for any fallout from the experiment on the lives of the babies and their families.
Dr. William Hurlbut, a Stanford University bioethicist whose advice He sought for more than a year before his experiment, said he felt sorry for the scientist, his wife and two young daughters.
I warned him things could end this way, but it was just too late, Hurlbut wrote in an email addressed to the AP; the director of the U.S. National Institutes of Health, Dr. Francis Collins; and gene-editing pioneer Jennifer Doudna at the University of California, Berkeley.
Sad story everyone lost in this (JK, his family, his colleagues, and his country), but the one gain is that the world is awakened to the seriousness of our advancing genetic technologies, Hurlbut wrote.
Dr. Eric Topol, who heads the Scripps Research Translational Institute in California, noted its almost unheard of for a scientist to get imprisoned but in this case the sheer recklessness and unethical behavior warranted it. Topol praised China for standing up for proper medical research conduct.
Doudna told the AP she was concerned about the mysterious legal process in China, but she said the sentences are a step toward bringing this case to closure and send a strong message to discourage other such work. (Doudna is paid by the Howard Hughes Medical Institute, which also supports APs Health and Science Department.)
As a scientist, one does not like to see scientists going to jail, but this was an unusual case, Doudna said. Hes work was clearly wrong in many ways.
Before setting up a lab at the Southern University of Science and Technology of China in Shenzhen, He studied in the U.S. The verdict accused him of colluding with Zhang Renli and Qin Jinzhou, who worked at medical institutes in the same province.
Zhang was sentenced to two years in prison and fined 1 million yuan, Xinhua said. Qin received an 18-month prison sentence, but with a two-year reprieve, and a 500,000 yuan fine.
Read the original post:
China confirms third birth of gene-edited baby; scientists involved get prison terms - WRAL Tech Wire
- New Stem Cell Approach Through Using Wavelength Laser Might have Discovered Why Humans Lose Hair - Tech Times - October 5th, 2021
- Stem cells and their role in lung transplant rejection - Michigan Medicine - October 5th, 2021
- Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial - KMVT - October 5th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - WIBW - October 5th, 2021
- Diabetic patient receives stem cell therapy - The Hindu - August 18th, 2021
- COVID- 19 Third Dose Approved for Certain Immunocompromised Individuals - the City of Cambridge - August 18th, 2021
- Acute Myeloid Leukemia Treatment: What You Need to Know - Healthline - August 18th, 2021
- 3D Bioprinting Market Size to Reach USD 2,687.8 Million in 2027 | Increasing Use of 3D Bioprinters in Medical Procedures, Training and Testing Along... - August 18th, 2021
- Some Residents Should Consider Third COVID-19 Vaccine Dose - Wyoming Department of Health - August 18th, 2021
- Stem Cell Alopecia Treatment Market Size, Demand, Growth, Trends, Segmentation and Forecasts to 2028 - The Market Writeuo - The Market Writeuo - August 18th, 2021
- Head-To-Head Phase 3 Trial To Evaluate BTK Inhibitors in MCL - Targeted Oncology - August 18th, 2021
- Safety of Stem Cell Therapy for Chronic Knee Pain Confirmed in New Study - SciTechDaily - August 5th, 2021
- Asia-Pacific Cell Therapy Market8 - Opportunities in the Approval of Kymriah and Yescarta - Markets Insider - August 5th, 2021
- Background should not be a barrier to access stem cell transplant treatment and care - PoliticsHome - August 5th, 2021
- Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy |... - August 5th, 2021
- Gliomagenesis is orchestrated by the Oct3/4 regulatory network. - Physician's Weekly - August 5th, 2021
- Improving the Treatment Gap in Diffuse Large B-Cell Lymphoma - Targeted Oncology - August 5th, 2021
- Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress - StreetInsider.com - August 5th, 2021
- MUHS, Nashik to conduct fellowship course in regenerative medicine - BSI bureau - August 5th, 2021
- FDA Hands Out Surprising Rejection of Meduxus and Medac's Treosulfan - BioSpace - August 5th, 2021
- Dr. Flowers on Efforts to Improve Frontline Treatment in DLBCL - OncLive - August 5th, 2021
- Future Directions in the Treatment of Polycythemia Vera - OncLive - August 5th, 2021
- FDA Grants Priority Review to Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-small Cell Lung Cancer - Business Wire - August 5th, 2021
- Cellino Appoints Industry Pioneer Robert J. Palay to the Board - Business Wire - August 5th, 2021
- Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF- Superfamily Member for the Treatment of Cancer - Yahoo Finance - August 5th, 2021
- Stemming the tide of stem-cell treatment scams - Houston Chronicle - July 22nd, 2021
- FDA gives speedy review to Bayer's Parkinson's stem cell therapy - - pharmaphorum - July 22nd, 2021
- John Theurer Cancer Center Investigators Participated in ZUMA-7 Study Showing Value of CAR T-Cell Therapy as Second-Line Treatment for Relapsed Large... - July 22nd, 2021
- Creative Medical Technology Holdings Announces MyeloCelz The Company's Second Regenerative Immunotherapy Product - PRNewswire - July 22nd, 2021
- Kadimastem Patent for cell selection of beta cells to Treat and Potentially Cure Diabetes was Granted in Japan - Yahoo Eurosport UK - July 22nd, 2021
- Bluebird, with little fanfare, is first to bring a second gene therapy to market - BioPharma Dive - July 22nd, 2021
- BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Disease - Yahoo Finance - July 22nd, 2021
- ViaCyte Appoints Dr. Jon Wilensky as Head of Surgery - PRNewswire - July 22nd, 2021
- Emerging Quadruplets, Novel Targets, and Immunotherapy Advances Personalized Medicine in Multiple Myeloma - OncLive - July 22nd, 2021
- Beyond CAR-T: New Frontiers in Living Cell Therapies - UCSF News Services - July 7th, 2021
- Sleeper cells, cells of origin and hematopoietic stem cells - Brain Tumour Research - July 7th, 2021
- Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML - PRNewswire - July 7th, 2021
- Researchers investigate whether stem cell therapy is safe and effective for treatment-resistant bipolar disease - Newswise - April 18th, 2021
- Stem Cell and Regenerative Therapy Market: Cell Therapy Segment to Dominate Global Market - BioSpace - April 18th, 2021
- First in the nation, FDA-approved Phase II mesenchymal stem cell therapy for Parkinson's disease begins - Newswise - April 18th, 2021
- Cellino Biotech developing tech to help scale stem cell therapies - MedCity News - April 18th, 2021
- Stem cell treatment needed to fight the good fight - Victoria Lookout - April 18th, 2021
- Being bionic: the future of regenerative medicine - Toronto Star - April 18th, 2021
- Treating chronic myeloid leukemia (CML): By phase and more - Medical News Today - April 18th, 2021
- Chemical conversion of human epidermal stem cells into intestinal goblet cells for modeling mucus-microbe interaction and therapy - Science Advances - April 18th, 2021
- Andres Isaias Combining Innovation and Excellence - Influencive - April 18th, 2021
- A Massive New Gene Editing Project Is Out to Crush Alzheimer's - Singularity Hub - April 18th, 2021
- Antibiotic Use Prior to Allogeneic Stem Cell Transplantation May Be Linked to Graft Vs Host Disease - Hematology Advisor - April 18th, 2021
- Mucopolysaccharidosis (MPS) Treatment Market Is Rising With Post COVID-19 Impact Analysis, Development, CAGR - Global Banking And Finance Review - April 18th, 2021
- The Recovery Room: News beyond the pandemic April 16 - Medical News Today - April 18th, 2021
- The Governments Watchful Eye on Fraud Stemming from Stem Cell Therapy - JD Supra - April 4th, 2021
- Uprooting Cancer: Innovative Hydrogel Rapidly Reverts Cancer Cells Back to Cancer Stem Cells - SciTechDaily - April 4th, 2021
- Multiple sclerosis: Recent research on causes and treatments - Medical News Today - April 4th, 2021
- First CAR T-Cell Therapy for Multiple Myeloma: Abecma - Medscape - April 4th, 2021
- Vitro Biopharma Retains Leading Health Care Executive as Acting Director of Regulatory Affairs & Director - Benzinga - April 4th, 2021
- Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy - DocWire News - April 4th, 2021
- Orca-T Offers an Alternative to HSCT With Improved Patient Experience - OncLive - April 4th, 2021
- Russell Health Highlighted in the Silicon Review's '50 Leading Companies of the Year 2021' - PRNewswire - April 4th, 2021
- Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy... - April 4th, 2021
- LGL Leukemia: Overview, Symptoms, and Treatment - Healthline - April 4th, 2021
- Funding the Next Generation of Cancer Therapies - Genetic Engineering & Biotechnology News - April 4th, 2021
- RenovaCare Announces Organizational Changes and Appointment of New Officers - GlobeNewswire - April 4th, 2021
- Stem Cell Therapy Market expected to reach USD 16.51 Billion by 2025 KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - March 8th, 2021
- Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine... - March 8th, 2021
- New Controversy for Stem Cell Therapy That Repairs Spinal Cords - The Great Courses Daily News - March 8th, 2021
- Cell Therapy for Cartilage Regeneration Gets a Boost With Hyaluronic Acid Enriched Chondrocytes in a 3D Tissue Engineering Platform - Business Wire - March 8th, 2021
- Scar-Forming Cells Switch to Producing New Neurons that Promote Functional Recovery in Mice after Spinal Cord Injury - Genetic Engineering &... - March 8th, 2021
- Moderna Hires Harvard Stem Cell Researcher Jonathan Hoggatt as Director of Hematology: What You Need to Know - Yahoo Finance - March 8th, 2021
- Stem Cell Banking Market Report 2021 | Growth and Opportunities Analysis - BioSpace - February 19th, 2021
- Global Cell Therapy Biomanufacturing Market (2020 to 2025) - Featuring Lonza Group, Merck & Novartis Among Others - ResearchAndMarkets.com -... - February 19th, 2021
- Off-the-Shelf NK Immunotherapy Is Safe and Promising in B-Cell NHL With Chemotherapy and Transplant - Targeted Oncology - February 17th, 2021
- Braunschweig Makes the Case for Earlier Use of CAR T-Cell Therapy in DLBCL - OncLive - February 17th, 2021
- Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection using ImmCelz - PRNewswire - February 17th, 2021
- Lineage to Host Virtual OPC1 Investor & Analyst Day on February 22, 2021 - Business Wire - February 17th, 2021
- Novartis, Gates Foundation pursue a simpler gene therapy for sickle cell - STAT - February 17th, 2021
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results - GlobeNewswire - February 17th, 2021
- Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation... - February 14th, 2021
- Zebrafish reveal regenerative protein that could inspire new treatments for muscle-wasting diseases and aging - FierceBiotech - February 11th, 2021
- Stem cell study illuminates the cause of an inherited heart disorder | Penn Today - Penn Today - February 11th, 2021
- Neurons from patient blood cells enable researchers to test treatments for genetic brain disease - Brown University - February 11th, 2021
